Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL66249 | 0.94 | MEN1 (0.75) | MEN1KMT2ATSHRCA5ACA5B | |
| SCHEMBL8897 | 0.94 | MEN1 (0.75) | MEN1KMT2ATSHRCA5ACA5B | |
| SCHEMBL27812586 | 0.94 | MEN1 (0.75) | MEN1KMT2ATSHRCA5ACA5B | |
| Water SCHEMBL2807134 | 0.88 | MEN1 (0.67) | MEN1KMT2ATSHRCA5ACA5B | |
| Water SCHEMBL16265933 | 0.88 | MEN1 (0.67) | MEN1KMT2ATSHRCA5ACA5B | |
| SCHEMBL5077442 | 0.88 | MEN1 (0.67) | MEN1KMT2ATSHRCA5ACA5B | |
| Water SCHEMBL4370443 | 0.88 | MEN1 (0.67) | MEN1KMT2ATSHRCA5ACA5B | |
| Water SCHEMBL900388 | 0.88 | MEN1 (0.67) | MEN1KMT2ATSHRCA5ACA5B | |
| Water SCHEMBL19665772 | 0.88 | MEN1 (0.67) | MEN1KMT2ATSHRCA5ACA5B | |
| Water SCHEMBL199336 | 0.88 | MEN1 (0.67) | MEN1KMT2ATSHRCA5ACA5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278067-B2 | Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes | REGULON, INC. (GR) | 2016-03-08 | — | — | US | disclosed |
| US-20140134232-A1 | Encapsulation of Plasmid DNA (Lipogenes™) and Therapeutic Agents with Nuclear Localization Signal/Fusogenic Peptide Conjugates into Targeted Liposome Complexes | REGULON, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20120183596-A1 | Encapsulation of Plasmid DNA (Lipogenes) and Therapeutic Agents with Nuclear Localization Signal/Fusogenic Peptide Conjugates into Targeted Liposome Complexes | REGULON, INC. | 2012-07-19 | — | — | US | disclosed |
| US-20030072794-A1 | Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes | REGULON, INC. | 2003-04-17 | — | — | US | disclosed |
| EP-1292284-A2 | ENCAPSULATION OF POLYNUCLEOTIDES AND DRUGS INTO TARGETED LIPOSOMES | Boulikas, Teni (US) | 2003-03-19 | — | — | EP | disclosed |
| WO-2001093836-A2 | ENCAPSULATION OF POLYNUCLEOTIDES AND DRUGS INTO TARGETED LIPOSOMES | BOULIKAS TENI (US) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140134232-A1 | Encapsulation of Plasmid DNA (Lipogenes™) and Therapeutic Agents with Nuclear Localization Signal/Fusogenic Peptide Conjugates into Targeted Liposome Complexes | TK1, LPXN, NASP | MEN1 2358/4885KMT2A 2469/4885TSHR 2749/4885 |
| US-20120183596-A1 | Encapsulation of Plasmid DNA (Lipogenes) and Therapeutic Agents with Nuclear Localization Signal/Fusogenic Peptide Conjugates into Targeted Liposome Complexes | TK1, LPXN, TK2 | MEN1 2080/4885KMT2A 2173/4885TSHR 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.